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Extensions of Randomization-Based Methods for Causal Inference
Abstract
In randomized experiments, the random assignment of units to treatment groups
justifies many of the traditional analysis methods for evaluating causal effects. Spec-
ifying subgroups of units for further examination after observing outcomes, however,
may partially nullify any advantages of randomized assignment when data are analyzed
naively. Some previous statistical literature has treated all post-hoc analyses homoge-
neously as entirely invalid and thus uninterpretable. Alternative analysis methods and
the extent of the validity of such analyses remain largely unstudied. Here Chapter 1
proposes a novel, randomization-based method that generates valid post-hoc subgroup
p-values, provided we know exactly how the subgroups were constructed. If we do not
know the exact subgrouping procedure, our method may still place helpful bounds on
the significance level of estimated effects. Chapter 2 extends the proposed methodology
to generate valid posterior predictive p-values for partially post-hoc subgroup analy-
ses, i.e., analyses that compare existing experimental data — from which a subgroup
specification is derived — to new, subgroup-only data. Both chapters are motivated
by pharmaceutical examples in which subgroup analyses played pivotal and controver-
sial roles. Chapter 3 extends our randomization-based methodology to more general
randomized experiments with multiple testing and nuisance unknowns. The results are
valid familywise tests that are doubly advantageous, in terms of statistical power, over
traditional methods. We apply our methods to data from the United States Job Train-
ing Partnership Act (JTPA) Study, where our analyses lead to different conclusions
regarding the significance of estimated JTPA effects. In all chapters, we investigate
the operating characteristics and demonstrate the advantages of our methods through
series of simulations.
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Chapter 1
Randomization-Based Inference for
Post-Hoc Subgroups
Lee and Rubin (accepted, 2015a)
1.1 Introduction
A causal effect is a comparison of potential outcomes for a common set of units. The
fundamental problem of causal inference is that at most one of the potential outcomes for
each unit can ever be observed (Rubin 1974). Statisticians generally consider randomized
experiments to be the gold standard for evaluating causal effects. In such instances, the
random assignment of experimental units to treatment groups justifies many of the widely-
used traditional analysis methods.
In addition to drawing conclusions about the entire collection of units, it is often desirable
to consider subsamples of the dataset at hand. When considering multiple individually
valid subgroup inferences, however, one must be aware of multiple comparisons, a well-
known but complicated issue studied by numerous statisticians, including Miller (1981) and
Tukey (1991). Traditional multiple comparisons adjustments (e.g., Bonferroni corrections)
are often severely conservative when subgroups overlap (see Chapter 3 and Westfall and
Young (1989)). Moreover, specifying subgroups of units after observing outcomes may make
it difficult to identify the number of comparisons being made, making such adjustments less
straightforward.
Furthermore, post-hoc decisions may partially nullify any advantage of randomized as-
signment when data are analyzed naively. As a simple example, consider a randomized
experiment with both female and male units. Suppose we observe no significant (at some
level) treatment effect over the whole study population but observe that the treatment ap-
pears significantly beneficial for females. If only then do we specify females as the subgroup
of interest, the traditionally calculated female p-value loses its traditional interpretation.
When examining post-hoc subgroup inferences, it is natural to expect overstatements of sta-
tistical significance. Yet, there is a statistical sense of “more valid” or “less valid” that is
ignored when all post-hoc analyses are homogenized as entirely invalid.
The issues associated with post-hoc subgroup inferences are not only theoretically chal-
lenging and interesting to statisticians, but also directly applicable to many fields of study,
including medicine and the social sciences (Assmann et al. 2000; Peck 2003; Rothwell 2005;
Wang et al. 2007). Post-hoc analyses can draw attention because of their evocative nature,
and they often provide evidence for possible future studies. Follow-up experiments, how-
ever, are often associated with large monetary costs and long delays before new data can
be obtained. Quick results and valid inferences from the dataset at hand, therefore, can
be beneficial to both drug developers and their patients, especially when dealing with rare
diseases. As opined by the clinical researchers of our motivating example, however, there
are currently no established guidelines for evaluating post-hoc subgroup inferences (Raghu
et al. 2004). Of course, the desire for timely analyses and valid inferences is not limited to
clinical trials.
Section 1.2 describes a recent pharmaceutical case with First Amendment legal implica-
tions, in which post-hoc subgroup inferences played a pivotal and controversial role. Here
we propose two approaches for obtaining valid p-values for such subgroups. First, in Section
1.3, we formulate a simulation model for the pharmaceutical experiment and use it to i)
2
demonstrate the operating characteristics of post-hoc estimates of subgroup average treat-
ment effects (SubATEs) and subgroup p-values, and ii) make model-based adjustments to
the subgroup p-values for more accurate interpretations. Second, in Section 1.4, we describe
a novel extension of a well-established statistical procedure that generates statistically valid
subgroup p-values, even when those subgroups are specified a posteriori, provided we know
exactly what procedure was used to construct those subgroups; if we do not know the exact
procedure, this method can still place helpful bounds on the significance level of estimated
effects. Although we do not have the raw data for the example described in Section 1.2,
we believe this approach could have an important impact on such examples and lead to
more accurate judgments about subgroup causal effects than the overly crude, dichotomous
classification of inferences as valid or invalid.
1.2 An Illustration
Idiopathic pulmonary fibrosis (IPF), a rare disease characterized by progressive scarring of
the lung tissue, currently affects nearly 100,000 people in the United States (Cleveland Clinic
2013; InterMune 2013). In addition to eventual respiratory failure, IPF is associated with
pulmonary hypertension (high blood pressure in the lungs), pulmonary embolism (blood
clots in the lungs), lung infections, heart attack, stroke, and lung cancer. As such, IPF is
debilitating and often fatal, with an estimated median survival time of two to three years
after diagnosis (Raghu et al. 2004). According to the United States National Institutes of
Health, there is no known cause of IPF (hence the name, “idiopathic”); as of this chapter’s
initial submission, no medication had yet been approved to treat it (A.D.A.M., Inc. 2013).
In 1999, InterMune began marketing the drug interferon gamma-1b, branded under the
name Actimmune, which was approved in 2000 by the United States Food and Drug Admin-
istration (FDA) for the treatment of two rare diseases unrelated to IPF. Nevertheless, the
drug could be, and was, prescribed off-label by pulmonologists to treat IPF (Stretch et al.
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2010), and InterMune conducted a series of clinical trials designed to achieve a label change
stating that Actimmune was effective for treating IPF.
However, the company’s randomized Phase III trial (GIPF-001) failed to meet its primary
endpoint regarding “progression-free survival” for its 330 IPF patients. The trial also failed
to meet any of its nine secondary endpoints, one of which was survival time (Stretch et al.
2010). Although the (two-sided) survival time p-value of 0.084 was insignificant based on the
330 patients (the standard FDA cutoff for p-value significance is 0.05), the Actimmune group
exhibited a 40% lower mortality rate than the control group. Furthermore, in the subgroup
of 254 patients with mild to moderate disease (defined by baseline predicted forced vital lung
capacity (FVC)), the Actimmune group exhibited a 70% lower mortality rate than the control
group. Depending on the FVC criterion, the p-value for the specified subgroup of patients
was as small as 0.004 (InterMune 2012). For any disease, especially one with consequences
as grave as IPF, a real survival benefit is of the utmost interest, and indications of a survival
benefit with such strong magnitude demand attention.
On August 28, 2002, under the direction of then-President and CEO W. Scott Harkonen,
InterMune issued a press release titled, “InterMune Announces Phase III Data Demonstrat-
ing Survival Benefit of Actimmune in IPF: Reduces Mortality by 70% in Patients With Mild
to Moderate Disease.” The press release stated that the GIPF-001 data “. . . demonstrate
a significant survival benefit in patients with mild to moderate disease randomly assigned
to Actimmune versus the control treatment (p = 0.004)” (InterMune 2012, p. 1). In a
medical sense, it may be reasonable to consider this subgroup of patients as highly relevant
because the disease in the excluded patients (classified as having severe disease) may have
already progressed beyond the point where any treatment could be effective. Nonetheless, as
noted in Section 1.1, statistical issues arise whenever subgrouping procedures are performed,
especially when they are performed after outcome data are observed.
Following the press release, the United States Department of Justice prosecuted Harko-
nen for “. . . fraudulently promoting the drug Actimmune” (United States v. Harkonen 2013),
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citing the statistical invalidity of post-hoc subgroup analyses. The prosecution argued that
Harkonen issued “. . . false and misleading information about the drug’s effectiveness in treat-
ing idiopathic pulmonary fibrosis” in order to increase InterMune’s revenue streams. On
September 29, 2009, a jury found Harkonen guilty of wire fraud; in March 2013, Harko-
nen’s conviction was affirmed by the Ninth Circuit of the United States Court of Appeals in
United States v. Harkonen. A petition for writ of certiorari was denied by the U.S. Supreme
Court in December 2013. For more legal context and discussion, see Brown (September 23,
2013). Legal arguments aside, the Actimmune case poses relevant and intriguing statistical
questions about the validity of Harkonen’s conclusions and of more general conclusions like
them. Are post-hoc subgroup inferences interpretable in any way, and to what extent should
they be trusted? What alternative analysis methods, if any, can be performed? Surely there
must be something more that statisticians can do than assert “invalidity.”
1.3 Actimmune Case Study: Simulation Model
In this section, we formulate a simulation model of the Actimmune case based on court doc-
uments, InterMune’s internal documents, and extended conversations with Harkonen’s legal
team and Harkonen himself. Our goal is to assess, under the null hypothesis of zero treatment
effect, how the presumably-used post-hoc subgrouping procedure distorts the traditionally
calculated subgroup p-value.
1.3.1 Randomized Experiment
Suppose we have a randomized experiment with units indexed by i = 1, ..., Ntotal and D
binary covariates: Xid = 1 with probability pd, d = 1, ..., D, where px = (p1, ..., pD) denotes
the vector of probabilities. Further, suppose that N1 units are randomly assigned to active
treatment, and N0 = Ntotal−N1 are randomly assigned to control. The binary experimental
outcome on which the treatment’s effectiveness is to be assessed is Y . Each unit has two
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potential outcomes: one under control, Yi(0), and one under the active treatment, Yi(1);
at most one of these can ever be observed (Rubin 1974, 2005). This notation is sufficient
under the stable unit treatment value assumption, which asserts no interference between
experimental units, as well as two well-defined outcomes (Rubin 1980, 1986). Under the
sharp null hypothesis of zero treatment effect, Yi(0) = Yi(1) for all i.
For our simulation, we draw a “successful” potential outcome Yi(·) with probability
P (Yi(·) = 1|Xi1, ..., XiD, β0, β1, ..., βD) = min(1, exp(β0 + β1Xi1 + ...+ βDXiD)),
where β0 is the baseline log rate of success and β1, ..., βD generate pseudo-correlations of
X1, ..., XD with Y . A positive βd value suggests that covariate d increases survival probability
multiplicatively when the other covariates are held constant. We select this model because it
facilitates straightforward parameter estimation for the simulation setup from the available
GIPF-001 data summaries; we check the model’s fit in Section 1.3.2. Formally, the success
probability of Y is truncated at 1, although boundary violations are not a concern within
our simulation.
We estimate the following parameter values for the simulation using the available Actim-
mune data summaries; these values are then regarded as “truth” throughout the simulation:
• Ntotal = 330, N1 = 162, N0 = 168. (In reality, some early dropouts were recorded; these
patients are ignored, as they were in the actual GIPF-001 trial analysis.)
• D = 4. The (pre-specified) relevant baseline covariates and their pd vales are:
– X1: Baseline predicted forced vital capacity (FVC) (≤ 60% vs. > 60%), p1 = 0.55
– X2: Use of prednisone or equivalent at study entry (no vs. yes), p2 = 0.76
– X3: Ratio of Actimmune dosage to body surface area (BSA)
(≤ 100 µg/m2 vs. > 100 µg/m2), p3 = 0.48
– X4: Days since IPF diagnosis (≤ 300 days vs. > 300 days), p4 = 0.51
• Y (0), Y (1) are survival indicators under the control and active treatments, respectively.
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• The β values are:
– Baseline FVC: β1 = 0.132
– Prednisone equivalent at baseline: β2 = −0.046
– Dosage-to-BSA ratio: β3 = −0.112
– Days since IPF diagnosis: β4 = 0.052
• The aggregate survival rate (across all patients) was 86.7%. Considering pd and βd as
known (d = 1, ..., 4), we then have four equations to obtain β0: for d = 1, ..., 4,
Overall survival probability = pd exp(β0 + βd) + (1− pd) exp(β0) ≈ 86.7%.
Using the mean of the four values of β0, we set β0 = −0.147.
1.3.2 Model Checks
To check the fit of our simulation model, we compare the key summary statistics of the
GIPF-001 data to the empirical distributions based on 10,000 random datasets generated
by our model (see Figure 1.1). The fit is excellent, both for the four covariates and for the
aggregate survival percentage, suggesting that our simulation model realistically reflects the
Actimmune scenario under the null hypothesis.
1.3.3 Post-Hoc Subgrouping Procedure
We outline Stages 0 and 1 of the Actimmune post-hoc subgrouping procedure as follows:
1. For each of the D = 4 covariates, the units are divided into two subgroups: those
satisfying Xid = 0 and those satisfying Xid = 1, thereby creating eight subgroups.
Each subject is in exactly four of the eight subgroups.
2. After observing outcome data, the researcher performs a traditional statistical test
on the entire dataset, resulting in a Stage 0 estimated average treatment effect (ATE)
7
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Figure 1.1: Comparison of actual observed covariate proportions and aggregate survival
proportion to simulation model-generated empirical distributions. Observed proportions
are represented by bold vertical lines. Empirical distributions are based on 10,000 model-
generated datasets.
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and corresponding p-value. Additionally, the researcher runs tests for each subgroup to
estimate eight SubATEs and their eight corresponding p-values. We use a two-sample
test for proportions, and the estimated ATE and SubATEs are calculated as differences
in survival proportions. Nine tests are conducted in total.
3. The researcher, presumably wanting to describe the group or subgroup for which the
treatment is most effective, selects — for Stage 1 reporting — the group or subgroup
that shows the most evidence of a positive treatment effect, defined by the smallest
p-value. If multiple subgroups share the minimum p-value, the largest subgroup (with
respect to the number of included units) that shares that minimum p-value is selected
for reporting. (If there are multiple largest subgroups that share the minimum p-value,
one of the eligible subgroups is selected for reporting at random.) If the analysis on
the entire dataset provides the smallest p-value, the Stage 0 p-value is reported.
In the Actimmune case, the Stage 1 subgroup included patients with baseline predicted
FVC greater than 60%. Stage 2 involves further modification of this subgroup. According
to court testimony by the GIPF-001 trial’s biostatistician, InterMune researchers followed
their Stage 1 analysis of FVC ≤ 60% and > 60% subgroups with additional analyses of
FVC < 55%, 55 − 70%, and > 70% subgroups, before eventually defining the final Stage 2
subgroup of FVC ≥ 55%. Suppose X(1) is chosen as the Stage 1 covariate. We reflect the
Stage 2 process in our simulation model as follows:
4. The X(1) categories from Stage 1 are further divided into two subcategories each,
according to a probability vector, resulting in four ordered subcategories of covariate
X(1). The four Actimmune subcategories were FVC: < 55%, 55− 60%, 60− 70%, and
> 70%. We use the probability vector (0.5, 0.5) because 36 of the 72 patients with
FVC ≤ 60% had FVC values below 55%, and we have no additional information about
the patients with FVC > 60%.
9
5. The nine possible Stage 2 subgroups are defined by unions of one or more adjacent
subcategories. For example, possible Stage 2 Actimmune subgroups included FVC
< 55%, FVC ∈ {55 − 60%, 60 − 70%} (i.e., 55% ≤ FVC ≤ 70%), and FVC ∈ {55 −
60%, 60 − 70%, > 70%} (i.e., FVC ≥ 55%). Similar to Stage 1, the researcher runs
a traditional statistical test to estimate nine SubATEs and their nine corresponding
p-values.
6. The final Stage 2 subgroup is the subgroup that shows the most significant subgroup
p-value. The Actimmune Stage 2 subgroup was FVC ∈ {55− 60%, 60− 70%, > 70%},
i.e., FVC ≥ 55%.
1.3.4 Simulation Results and Case Discussion
We generate 10,000 random datasets according to the null model described in Section 1.3.1
and perform Stage 1 and Stage 2 subgroup selection and analysis for each. Stage 0 tests
(performed on the entire dataset, before post-hoc subgroup selection) behave conventionally
under the null hypothesis of zero treatment effect: estimated ATEs are centered at zero
and p-values are close to uniformly distributed, allowing for valid, traditional significance
testing of estimated causal effects. After Stage 1, however, as expected, estimated SubATEs
are biased upward, and subgroup p-values are skewed toward zero. Simulation results and
comparisons are displayed in Table 1.1 and Figure 1.2.
Subgroup Traditional p-value
Observed Empirical Model Quantiles
Actimmune 5% 25% 50% 75% 95%
Stage 0 0.08 0.05 0.25 0.50 0.75 0.95
Stage 1 0.02 0.01 0.05 0.14 0.29 0.58
Stage 2 0.004 0.004 0.03 0.08 0.17 0.39
Table 1.1: Comparison of observed Actimmune p-values to empirical quantiles of Stage
0, Stage 1, and Stage 2 p-values based on 10,000 simulated replications under the null
hypothesis.
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Figure 1.2: Empirical distribution of Stage 1 and Stage 2 results based on 10,000 simulated
replications under the null hypothesis. Estimated SubATEs in both stages are biased upward
rather than centered at zero. Bold vertical lines are placed at zero to highlight the bias.
Subgroup p-values in both stages are skewed toward zero, rather than uniformly distributed,
inflating the apparent significance of the post-hoc subgroup analyses.
Naturally, Stage 2 estimated SubATEs are further biased upward from Stage 1, with
subgroup p-values further skewed toward zero. However, although the additional subgroup
modification in Stage 2 often inflates significance further than Stage 1, the effect is not
dramatic. In fact, as shown in the right panel of Figure 1.3, Stage 1 and Stage 2 subgroup
p-values are actually identical in over 30% of simulated replications. On the whole, the
simulation results illustrate that even when no treatment effect truly exists, Stage 1 and
Stage 2 subgroup analyses often falsely suggest that the active treatment has a significant
causal effect on the outcome for the chosen subgroup.
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Figure 1.3: Empirical distribution of p-value ratios based on 10,000 simulated replications
under the null hypothesis, with observed ratios from the GIPF-001 trial marked by bold
vertical lines. Left: ratio of Stage 1 to Stage 0 p-values. Middle: ratio of Stage 2 to Stage 0
p-values. Right: ratio of Stage 2 to Stage 1 p-values.
The Actimmune Stage 0 p-value for survival was 0.08 — a p-value that may give some
indication of a clinical benefit, although not technically “statistically significant” at the pre-
specified 0.05 level. The Stage 1 and Stage 2 p-values from the Actimmune trial were 0.02
and 0.004, respectively. These values represent small fractions of the Stage 0 p-value (25%
and 5%, respectively) and would both be considered highly significant at the 0.05 level if
they had resulted from one analysis specified a priori. In order to interpret the a posteriori
subgroup p-values more properly, we evaluate the frequency of such p-values under the null
hypothesis, according to our simulation model.
After accounting for the post-hoc subgrouping procedure described in Section 1.3.3, both
Stage 1 and Stage 2 p-values make dramatic movements toward insignificance. Specifically,
based on the simulations under the null hypothesis, the Stage 1 p-value of 0.02 is even less
significant than the Stage 0 p-value, moving from the calculated 0.02 to 0.11, as suggested by
Figure 1.2. The Stage 2 p-value moves from the calculated 0.004 to 0.044; although the Stage
2 p-value technically remains “statistically significant” at the 0.05 level, its interpretation as
overwhelming evidence of the drug’s survival benefit no longer applies. To assess the inflation
of statistical significance by stage, we also evaluate the frequency of p-value ratios of Stage
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1 and 2 p-values to Stage 0 according to our simulation model. Under the null hypothesis,
such extreme ratios of inflation are moderately, but not extremely, unlikely, occurring in
about 32% and 11% of simulated replications, respectively (see Figure 1.3). Stage 1 to Stage
2 inflations as extreme as Actimmune’s occur in about 9% of simulated replications. A
complete evaluation of frequency characteristics is displayed in Table 1.2.
Observed Simulation Model Under Null Hypothesis
p-value Actimmune Proportion As Extreme As Observed
Stage 0 0.08 8.0%
Stage 1 0.02 11.2%
Stage 2 0.004 4.4%
Observed Simulation Model Under Null Hypothesis
p-value Ratio Actimmune Proportion As Extreme As Observed
Stage 1 to 0 0.25 32.5%
Stage 2 to 0 0.05 11.2%
Stage 2 to 1 0.2 8.7%
Table 1.2: Observed Actimmune test statistics and corresponding proportions of simulated
replications for which significance or significance inflation was as extreme. Based on 10,000
simulated replications under the null hypothesis.
Because the simulation-based Stage 2 p-value is near the border of 0.05-level significance,
we can surmise that accounting for more extreme subgrouping procedures would indeed push
this p-value into traditional insignificance, tempering the apparent evidence of a treatment
effect. More extreme procedures in the context of the Actimmune may also be more real-
istic. Namely, recall that mortality was one of nine secondary endpoints in the GIPF-001
trial; on the other hand, the subgrouping procedure in Section 1.3.3, for simplicity, treated
mortality as the sole outcome of interest. Post-hoc subgrouping procedures that incorporate
the primary endpoint, the eight other secondary endpoints, or possibly additional covariates
would very likely push the Stage 2 p-value to insignificance. (In fact, a follow-up study to the
GIPF-001 trial showed no survival benefit from Actimmune over a placebo for a somewhat
similar subgroup of patients (King Jr et al. 2009).)
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1.4 A Randomization-Based Approach for Generating
Valid Post-Hoc Subgroup p-values
A customized simulation model, such as the Actimmune one described in Section 1.3, will
always require certain assumptions and may not always be plausible. We now propose a
randomization-based approach that does generate valid p-values, provided we know exactly
how the subgroups were constructed. If we do not know exactly how they were constructed,
the method can still generate helpful bounds on the significance level associated with esti-
mated causal effects, using reasonable approximations of the post-hoc procedure.
The distributions of the estimated ATE and of the associated p-value from the exper-
iment can be viewed under the sharp null hypothesis of no treatment effect as functions
solely of the random assignment vector. As an extension, the distributions of any estimated
SubATE and traditionally calculated subgroup p-value can also be viewed as functions solely
of the assignment vector, when the subgrouping procedures are known. Thus, by generat-
ing a random assignment vector according to the assignment mechanism, we can generate
an estimated SubATE and a corresponding subgroup p-value for the post-hoc subgrouping
procedure under this sharp null hypothesis. Over repeated realizations of the assignment
vector, we can obtain the null randomization distributions of these subgroup statistics and
thereby evaluate the significance of the original, observed subgroup statistics.
The basic form of this approach, in which no post-hoc subgrouping occurs, was first
proposed by Fisher (1935) and has gained popularity through the Fisher exact test. The
exact test is typically only used in situations with small sample sizes because the traditional
normality-based asymptotic tests are often sufficiently accurate for situations with even mod-
erate sample sizes, and computation of randomization-based tests for larger samples has been
computationally demanding until recently. However, it is clear that for post-hoc subgroup
analyses, the traditional tests are no longer interpretable in the usual fashion. Addition-
ally, increased computational power has made larger-scale randomization tests relatively
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manageable (for example, see Lee, Dasgupta, and Rubin (submitted) and the R package
randomizationInference (Lee and Dasgupta 2013–2015)).
Our main contribution is to re-frame the observed post-hoc procedure as just one path,
randomly realized from a larger decision tree. In other words, our solution considers what
subgrouping and inferential steps would have been taken if the data had realized under a
different randomization. Our method is similar in spirit to the randomization-based meth-
ods described in Brown and Fears (1981) and Westfall and Young (1989) for pre-specified
multiple comparisons of multivariate binomial outcomes. In fact, the methods coincide when
the post-hoc inference is the result of a simple set of multiple comparisons; in that setting,
Westfall and Young (1989) showed that such randomization-based methods are more pow-
erful than traditional multiple comparisons adjustments (e.g., Bonferroni). Our method, by
contrast, applies more broadly because we do not assume an a priori fixed set of groups
being examined or a specific type of experimental outcome (e.g., binomial). Namely, our
method is capable of handling complicated post-hoc inferential procedures that may involve
non-standard test statistics — such as the sequential selection procedure outlined in Section
1.3, whose examination set varies with the observed outcome data. By outputting a “true
randomization-based p-value” for the observed dataset, the proposed test allows us to as-
sess the significance of estimated causal effects from post-hoc subgroups in a valid manner,
without any additional model assumptions and without relying on asymptotic approxima-
tions. We see the proposed modified randomization test as a compelling and straightforward
extension of Fisher’s ideas, much like the re-randomization p-values discussed in Morgan
and Rubin (2012). We believe this randomization-based approach could have an important
impact and could help, in some cases, alleviate the need for costly and time-consuming
follow-up studies.
The modified randomization test for valid post-hoc subgroup p-values is as follows:
1. Specify precisely the post-hoc subgrouping procedure (e.g., Stage 1 and 2 Actimmune
procedures) and the subgroup test statistic of interest, T (e.g., Stage 2 p-value).
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2. Perform the post-hoc subgrouping procedure on the observed dataset to obtain the
observed subgroup test statistic, T obs.
3. Impute the missing potential outcomes under the sharp null hypothesis.
4. Draw a random hypothetical assignment vector according to the actual assignment
mechanism. Treating the hypothetical assignment vector as true, create the corre-
sponding hypothetical observed dataset using the complete set of observed and imputed
potential outcomes.
5. Perform the post-hoc subgrouping procedure and calculate T on the hypothetical ob-
served data to obtain T hyp. Record whether this statistic is as extreme as T obs.
6. Repeat Steps 4–5 a reasonable number of times. If sample size is small, it may be pos-
sible to cycle through all possible assignment vectors. In most cases, however, drawing
a large number (e.g., 10,000, depending on computational constraints) of random as-
signment vectors, with replacement, provides a sufficient approximation.
7. Calculate the proportion of hypothetical observed datasets for which T hyp is as extreme
as or more extreme than T obs. This is the “true randomization-based” p-value (or
Fisher p-value). If all possible permutations are used, this proportion is the exact
Fisher p-value.
In some applied settings, it may be difficult to specify the post-hoc procedure exactly as it
occurred. In such cases, our method may still place helpful bounds on the significance level of
estimated effects, using reasonable approximations of the post-hoc procedure. By specifying
a “conservative” version of the post-hoc procedure that results in the same observed test
statistic, we can establish an upper bound for the true p-value of the estimated effect. We
classify a version of the procedure as “conservative” if it leads to more significant estimated
effects, in expectation, than the actual procedure. If this upper bound is already below the
pre-specified significance cutoff, then we are assured that the true p-value is also below the
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cutoff. Similarly, specifying a “liberal” version of the post-hoc procedure — one that leads
to less significant estimated effects in expectation — can establish a lower bound for the true
p-value. If the lower bound is already above the pre-specified cutoff, then we are assured
that the true p-value is also above the cutoff.
To demonstrate our method’s properties, we apply the proposed modified randomization
test to 1,000 randomly generated datasets from the Actimmune simulation model, with
the Stage 2 p-value as the subgroup test statistic. For each dataset, we draw 100 random
hypothetical assignment vectors (chosen for computational convenience) and calculate a
randomization-based p-value. As shown in Figure 1.4, the randomization-based p-value
achieves the desired property of being approximately uniformly distributed under the null
hypothesis. Given the actual GIPF-001 trial data, this randomization-based approach could
help us provide a more definitive judgment about the statistical significance of the treatment
effect on the FVC ≥ 55% subgroup. Because we do not have the raw dataset, however, it is
difficult to make such a judgment without utilizing the simulation model from Section 1.3.
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Figure 1.4: Empirical distribution of the randomization-based p-value based on 1,000 ran-
domly generated datasets under the null hypothesis. For each dataset, the randomization-
based p-value is calculated using 100 random draws of the assignment vector. The desired
property of approximate uniformity is achieved, with approximately 5% of p-values below
0.05 (denoted by the bold vertical line).
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This randomization-based method makes no distributional assumptions about the test
statistic and can thus be particularly useful when the test statistic is unconventional, as seen
in the Actimmune case. The method, however, is not limited to assessing estimated causal
effects in post-hoc subgroups; in fact, it is valid for assessing causal effects under very general
settings, including, but not limited to, situations examining multiple outcomes of interest,
differences in outcome spreads, differences in outcome ranks, and subgroups resulting from
pre-specified decision trees.
1.5 Conclusion
The severity of diseases like IPF demands valid and swift evaluations of drug efficacy, but
the Actimmune case is just one of many real-world examples in which post-hoc subgroup
inferences have played an important role. Due to the undeniable popularity of exploratory
post-hoc analyses and the understandable desire to avoid additional data collection costs,
the statistically valid consideration of these issues deserves investigation. We believe the pro-
posed randomization-based method could have an important impact on post-hoc subgroup
analyses, thereby leading to more accurate and more efficient judgments about subgroup
causal effects.
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Chapter 2
Randomization-Based Inference for
Partially Post-Hoc Subgroups
Lee and Rubin (accepted, 2015b)
2.1 Introduction
Subgroup causal effects are often of scientific interest in randomized experiments. When
subgroups are specified after observing outcomes, however, the estimated subgroup effects
and p-values produced by traditional statistical methods do not have the typically desired
repeated sampling properties, as described in Chapter 1. Traditional multiple comparisons
(e.g., Bonferroni) adjustments tend to be overly conservative when subgroups overlap (see
Chapter 3 and Westfall and Young (1989)). Moreover, post-hoc decisions often make it
difficult to specify the number of comparisons being made, making such adjustments less
straightforward. “Partially post-hoc” subgroup analyses, which compare existing data —
from which the subgroup specification is derived — to new, subgroup-only experimental
data, are further complicated.
Here we describe a motivating example faced by the U.S. FDA in which a partially
post-hoc subgroup analysis instigated statistical debate about a medical device’s efficacy.
We provide a statistical framework to clarify the source of statistical invalidity. We then
propose a randomization-based method for generating valid posterior predictive p-values for
such partially post-hoc subgroups. Although we do not have raw data for the particular
example, we investigate the method’s operating characteristics through a series of simula-
tions, showing that it exhibits both a valid type I error rate and substantial power under
reasonable alternative hypotheses.
2.2 The Durolane Trials
In March 2006, Swedish medical device company Q-Med AB submitted its medical device
Durolane to the FDA for pre-market approval. Durolane is a viscous gel intended to treat
osteoarthritic knee pain, administered through intra-articular (into-the-joint) injection. Prior
to FDA review, the device had already been approved in a number of countries across Europe
and Asia. As evidence of Durolane’s efficacy, Q-Med submitted analyses of data from three
randomized clinical trials.
Q-Med initially conducted two randomized, double-blind experiments attempting to
demonstrate Durolane’s superiority to a saline placebo (control), measuring each patient’s
pre- and post-treatment pain scores on the Western Ontario and McMasters Universities
Osteoarthritis Index (WOMAC). Higher WOMAC scores translate to higher levels of pain;
patients were deemed positive responders to treatment if their WOMAC pain scores were
reduced by at least 40% and at least 5 points on the 0–20 point scale. Comparisons of re-
sponder rates in Studies 1 and 2 produced p-values of 0.53 and 0.49, respectively, neither of
which are considered close to statistically significant by the FDA (the standard FDA cutoff
for significance is 0.05).
After observing and un-blinding outcome data from Studies 1 and 2, Q-Med combined
and filtered the data for a post-hoc subgroup analysis. Patients without effusion (fluid
accumulation in the knee joint) and without baseline polyarticular pain — 284 (50.4%) of
the 564 total patients — were included in the selected subgroup. Researchers asserted that
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including patients with effusion and polyarticular pain would make it “. . . difficult to observe
a treatment effect because the presence of these conditions leads to considerable variability
in the WOMAC assessment” (Q-Med, AB 2009). The subgroup, however, was not specified a
priori. Within the subgroup, Q-Med found a statistically significant difference in responder
rates, boasting a drastically decreased p-value of 0.0013.
Per FDA’s request, Q-Med conducted a third clinical trial to confirm this affirmative
result for the specified patient subpopulation. All Study 3 patients satisfied the covariate
inclusion criteria specified in the post-hoc analysis of Studies 1 and 2. Instead of using a
placebo control group in Study 3, however, Q-Med decided to compare Durolane to the drug
methylprednisolone in a non-inferiority trial. Although methylprednisolone is currently an
approved standard of care for osteoarthritic knee pain, there exist concerns about its side
effects, particularly its tendency to destroy cartilage over time; Durolane is purportedly able
to avoid this detrimental side effect. Based on 442 patients, Study 3 successfully showed
Durolane’s non-inferiority to methylprednisolone. But because no saline control group was
included, Study 3 alone did not provide direct evidence, as desired by the FDA, for Durolane’s
superiority to a saline placebo in reducing knee pain.
Because there was no placebo control group for Study 3, Q-Med used covariate-matched
saline placebo patients from Studies 1 and 2 to assess Durolane’s effectiveness. The selected
historical placebo controls (i) met Study 3 covariate inclusion criteria, and (ii) provided
sufficient covariate balance in comparison to the Study 3 Durolane treatment group, as
determined by a propensity score model (Rosenbaum and Rubin 1983). Observed outcomes
were not used in the selection of historical controls. The comparison of historical controls
from Studies 1 and 2 to Durolane patients from Study 3 favored Durolane, with a statistically
significant p-value of 0.047. Nevertheless, in August 2009, the FDA rejected Durolane for
sale in the U.S.
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2.3 A Statistical Framework
Here we describe a statistical framework and explore the implications of using historical
controls in the Durolane context. We argue why the combined subgroup p-value is invalid (in
terms of type I error) and demonstrate that balancing covariate profiles (e.g., via propensity
score matching) cannot fully repair its validity.
2.3.1 Experiment 1 and Post-hoc Subgroup Specification
Suppose we have N1 patients in Experiment 1 (representing Durolane Studies 1 and 2 col-
lectively), each defined by a single, binary covariate X (e.g., male/female) and randomly
assigned to the control or active treatment (indicated by W ). Let Y be a binary experimen-
tal outcome representing whether or not a patient “responds” to the assigned treatment (e.g.,
in terms of having reduced knee pain). The “Science” table (Rubin 2005) for Experiment 1
and its observed values under a particular assignment are shown in Table 2.1. Each patient
has two potential outcomes (Neyman 1923), only one of which can ever be observed (Rubin
1974). This notation is sufficient under the stable unit treatment value assumption, which
asserts no interference between experimental units, as well as two well-defined outcomes
(Rubin 1980). Unit i, j represents the jth unit from Experiment i.
Experiment 1
Covariate Potential Outcomes Assignment Observed Outcomes
Unit (i, j) Xi,j Yi,j(0) Yi,j(1) W
obs
i,j Yi,j(0) Yi,j(1)
1, 1 0 Y1,1(0) Y1,1(1) 0 Y
obs
1,1 ?
1, 2 1 Y1,2(0) Y1,2(1) 0 Y
obs
1,2 ?
1, 3 0 Y1,3(0) Y1,3(1) 1 ? Y
obs
1,3
. . . . . . . . .
1, N1 1 Y1,N1(0) Y1,N1(1) 1 ? Y
obs
1,N1
Table 2.1: The Science table for Experiment 1 (left) its and corresponding observed values
under a particular assignment (right).
Suppose that after Experiment 1 outcomes are observed, the researcher calculates sub-
group p-values for each possibly scientifically relevant subgroup, defined by X values. In
22
the setting with a single binary covariate X, there are three possible subgroups: X = 0,
X = 1, and X ∈ {0, 1}. The researcher then presumably identifies the subgroup S for which
the active treatment appears to have the most beneficial effect with respect to Y , e.g., the
subgroup with the most significant p-value in favor of the active treatment.
2.3.2 Experiment 2
Experiment 2 (representing Durolane Study 3) consists of N2 patients, all of whom satisfy
the subgroup criteria of S and are assigned to active treatment; there are no control pa-
tients. In reality, Durolane’s Experiment 2 introduced a new, third treatment condition
(methylprednisolone, see Section 2.2). However, Q-Med’s ultimate goal was to satisfy FDA’s
request to compare Durolane to the saline placebo (the control from Experiment 1). The
Experiment 2 patients assigned to methylprednisolone are not relevant for this purpose and
are thus ignored here.
Without loss of generality, suppose that the X = 1, e.g., female, subgroup is chosen from
Experiment 1. Then Experiment 2 consists entirely of female patients assigned to the active
treatment; the observed values of the Experiment 2 Science table are shown in Table 2.2.
Experiment 2
Covariate Assignment Observed Outcomes
Unit (i, j) Xi,j W
obs
i,j Yi,j(0) Yi,j(1)
2, 1 1 1 ? Y obs2,1
2, 2 1 1 ? Y obs2,2
2, 3 1 1 ? Y obs2,3
. . . . . .
2, N2 1 1 ? Y
obs
2,N2
Table 2.2: The observed values of the Science table for Experiment 2.
2.3.3 Combined Subgroup Analysis
Because Experiment 2 outcomes are realized after S is specified, Experiment 2 data can be
used to estimate the subgroup average treatment effect (SubATE) validly through traditional
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statistical methods. For instance, if control patients were also included in Experiment 2, the
data from Experiment 2 alone could generate a valid subgroup p-value. However, compar-
isons using Experiment 1 control patients and Experiment 2 treatment patients cannot be
handled in the same manner.
Consider the following two quantities: (i) τˆ1,S = Y¯
obs
1,j∈S(1)−Y¯ obs1,j∈S(0), and (ii) τˆcombined,S =
Y¯ obs2,j∈S(1)−Y¯ obs1,j∈S(0). The first quantity, τˆ1,S, represents the estimated SubATE for S from Ex-
periment 1, from which the selected subgroup specification is derived. The second, τˆcombined,S,
represents the estimated SubATE for S obtained by comparing Experiment 1 control pa-
tients and Experiment 2 treatment patients. The combined subgroup analysis calculates
τˆcombined,S and generates an associated subgroup p-value.
2.3.4 Invalidity Under the Null Hypothesis
Suppose that the null hypothesis of zero treatment effect is true. Because the specification
of S is a function of observed Experiment 1 outcomes, the expectation of τˆ1,S (over the
randomization) is positive, and its associated p-value is skewed right, making traditional
testing invalid in terms of type I error (see Chapter 1). Conceptually, E(τˆ1,S) > 0 because
τˆ1,S is the maximum or near-maximum of several estimated SubATEs from Experiment 1.
Examining the two terms that comprise τˆ1,S, we expect Y¯
obs
1,j∈S(1) to be high and Y¯
obs
1,j∈S(0)
to be low because of the subgroup specification; in other words, we expect Experiment 1
treatment patients in S to have good outcomes, and Experiment 1 control patients in S
to have poor outcomes, because such outcome information was used to select S in the first
place.
In addition, because τˆcombined,S shares one term with τˆ1,S, we can see by the linearity of
the expectation operator that τˆcombined,S also has a positive expectation and a skewed-right
p-value under the null hypothesis. Although Y¯ obs2,j∈S(1) is realized after S is specified, the
carry-over usage of Y¯ obs1,j∈S(0) renders traditional testing of τˆcombined,S invalid (though, one
could argue, “less invalid” than testing of τˆ1,S).
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Finally, note in this setting that the historical controls in the combined subgroup anal-
ysis have covariate profiles (e.g., X = 1) that exactly match the Experiment 2 treatment
patients. Here the statistical problem is rooted not in any discrepancies between control
and treatment covariate profiles, but in the usage of observed Experiment 1 outcomes un-
der the false assumption that they are independent of the subgroup specification. Any
traditionally-calculated subgroup p-value for τˆcombined,S cannot be valid, regardless of any
covariate balancing (e.g., propensity score matching) techniques designed to mitigate that
invalidity.
2.4 Valid Randomization-based p-values for Post-hoc
Subgroups in the Presence of Nuisance Unknowns
Chapter 1 introduced a randomization-based approach for generating valid post-hoc sub-
group p-values, motivated by earlier ideas about randomization due to Fisher (1935). The
fundamental insight is to specify the decision tree that led to the final test statistic value,
considering what subgrouping and inferential steps would have been taken if the data had
been realized under a different randomization. The approach entails (i) specifying a precise
post-hoc subgrouping procedure and an accompanying test statistic, (ii) calculating the test
statistic on the observed data, (iii) imputing the missing potential outcomes in the study
under a sharp null hypothesis, (iv) repeatedly drawing random hypothetical assignments
according to the assignment mechanism and calculating test statistic values on the corre-
sponding hypothetical datasets to construct the null randomization distribution of the test
statistic, and (v) comparing the observed test statistic value against its null randomization
distribution.
Calculating test statistic values on hypothetical data from a single experiment under a
sharp null hypothesis is straightforward. For example, under the sharp null hypothesis of
zero treatment effect, the missing potential outcomes can be imputed exactly as observed for
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each unit. The test statistic is then calculated using the hypothetical assignment and corre-
sponding hypothetical observed data, given the specified subgrouping procedure. However,
in settings with multiple experiments — including one or more that occur after the subgroup
specification — constructing the null randomization distribution of the test statistic requires
some ingenuity.
Consider our example from Section 2.3, in which females (X = 1 patients) comprise the
selected subgroup, S. The final test statistic, τˆcombined,S, compares outcomes from female
Experiment 1 control patients with outcomes from Experiment 2 treatment patients, where
by construction, all of the Experiment 2 patients are female. But what if males had exhibited
a more beneficial estimated treatment effect than females in Experiment 1? Presumably,
Experiment 2 would then have included only males; the experimental sample for Experiment
2 would have been completely different.
Here we propose an extension of the aforementioned method that generates valid posterior
predictive p-values (Rubin 1984; Meng 1994) in the presence of nuisance unknowns, e.g., male
Experiment 2 outcomes. We expand the Experiment 2 Science table, conceptualizing it as an
augmented experiment with N ′2 patients (N
′
2 > N2), containing patients with the same mix
of X values as Experiment 1 and filled with missing data. For Experiment 2 patients that
exist in reality (i.e., females), potential outcomes under active treatment are observed, but
potential outcomes under control are missing (unobserved). For Experiment 2 patients that
exist only in our augmented framework (i.e., males), both potential outcomes are missing.
The observed and unobserved values of the augmented Experiment 2 Science table are shown
in Table 2.3.
Because the male treatment potential outcomes are not observed in Experiment 2, values
of τˆcombined,S under hypothetical randomizations can be considered random variables, with
uncertainty resulting from these missing potential outcomes. Given a set of imputed val-
ues, however, we can construct the randomization distribution of τˆcombined,S and calculate a
randomization-based p-value. Thus, by multiply imputing (Rubin 1987) the missing male
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Experiment 2
Covariate Assignment Potential Outcomes
Unit (i, j) Xi,j W
obs
i,j Yi,j(0) Yi,j(1)
2, 1 1 1 ? Y obs2,1
2, 2 1 1 ? Y obs2,2
2, 3 1 1 ? Y obs2,3
. . . . . .
2, N2 1 1 ? Y
obs
2,N2
2, N2 + 1 0 1 ? ?
2, N2 + 2 0 1 ? ?
. . . . . .
2, N ′2 0 1 ? ?
Table 2.3: The observed and unobserved values of the augmented Experiment 2 Science
table.
potential outcomes according to a distributional model that assumes the null hypothesis,
they can be “integrated out” to produce a posterior predictive p-value; the posterior predic-
tive p-value is the average p-value over the multiple imputations of the missing treatment
potential outcomes.
Under the null hypothesis, the posterior predictive distribution of the missing treatment
potential outcomes is informed by the observed Experiment 1 potential outcomes for both
control and treatment patients. In the framework with binary outcomes and two indepen-
dent covariate subgroups (males versus females), there are two parameters to model for
imputation: the probability of a successful male outcome and the probability of a successful
female outcome. A typical Bayesian model involves two independent Beta priors and Bino-
mial likelihoods, leading to a Beta-Binomial posterior predictive distribution for the missing
treatment potential outcomes. Modeling is further simplified by the fact that the treatment
potential outcomes in Experiment 2 need to be imputed only for the male patients; the
parameter governing the female potential outcomes can be ignored because it is not needed.
For a post-hoc subgroup test statistic T , the full procedure for obtaining a posterior
predictive p-value in the two-experiment setting is as follows:
1. Specify precisely the post-hoc subgrouping procedure and the subgroup test statistic
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of interest, T (e.g., τˆcombined,S).
2. Perform the post-hoc subgrouping procedure on the observed dataset to obtain the
observed subgroup test statistic, T obs.
3. Using the augmented Experiment 2 framework, multiply impute the missing treat-
ment potential outcomes (e.g., M times), using their posterior predictive distributions
according to a distributional model that assumes the null hypothesis. M is a large
number (e.g., 10,000) that controls the Monte Carlo integration error.
4. For each of the M imputed datasets, calculate a randomization-based p-value for T
according to the actual assignment mechanism(s) and specified subgrouping proce-
dure (see Lee and Rubin accepted, 2015a), treating the imputed values as true. The
randomization-based p-value is the proportion of hypothetical randomizations for which
the corresponding test statistic value, T hyp, is as extreme as or more extreme than T obs.
5. The posterior predictive p-value for the null hypothesis with respect to T equals the
average of the M randomization-based p-values.
The method outlined above can be viewed as a form of data augmentation (Tanner and
Wong 1987), with the expanded Experiment 2 population making it possible to obtain a
posterior predictive p-value for T . Rubin (1998) described a similar procedure in a different
setting, in order to obtain a posterior predictive p-value for the complier average causal effect
(CACE) in a single experiment with non-compliance. In that setting, the nuisance unknowns
were the missing compliance statuses of the patients in the experiment who were assigned to
the control treatment. In the same paper, a computational shortcut was identified: for each
of the M imputed datasets, only one hypothetical assignment needs to be drawn in Step
4. The individual randomization-based p-values then equal either 0 or 1, and the posterior
predictive p-value is the average of the indicators.
As mentioned in Chapter 1, specifying a post-hoc procedure exactly as it occurred may be
difficult. In such cases, the randomization-based posterior predictive p-values can still place
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helpful bounds on the significance level of estimated subgroup effects by using reasonable
approximations that place limits on the post-hoc procedure.
2.5 Operating Characteristics
2.5.1 Simulation Setup
To evaluate the operating characteristics of the proposed method, we simulate random
datasets under various treatment effect hypotheses. We first randomly sample N1 = 500
patients for Experiment 1, drawing from a population of 50% females and 50% males. We
randomly assign N1/2 of these patients to control and the other N1/2 to active treatment.
We then draw random Bernoulli outcomes according to the probabilities in Table 2.4.
Males Females
Control Active Treatment Control Active Treatment
Null hypothesis A 0.50 0.50 0.50 0.50
Null hypothesis B 0.20 0.20 0.80 0.80
Alternative hypothesis A 0.50 0.55 0.50 0.55
Alternative hypothesis B 0.20 0.30 0.80 0.90
Table 2.4: Simulated outcome success (“response”) probabilities under various treatment
effect hypotheses.
After observing Experiment 1 outcomes, we specify the subgroup S for further study.
There are three possible choices for S: males, females, or all patients; S is the subgroup
exhibiting the smallest p-value based on control versus treatment Experiment 1 responder
rates. (If multiple subgroups share the smallest p-value, the one in that pool with the largest
number of included units is selected. If multiple subgroups share the smallest p-value and
the largest sample size within that pool, one of them is selected at random.)
Experiment 2 is conducted with new patients, all of whom satisfy the criterion of S
and are assigned to active treatment. The combined subgroup p-value is calculated for
τˆcombined,S, comparing Experiment 2 treatment units in S to Experiment 1 control units in
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S. Randomization-based posterior predictive p-values are then generated according to the
procedure described in Section 2.4.
2.5.2 Simulation Results
Under the null hypotheses described in Table 2.4, both the Experiment 1 and combined
(Experiments 1 and 2) subgroup p-values are invalid in terms of type I error, i.e., both
subgroup p-values incorrectly reject the null hypothesis more often than desired by the
nominal significance level. Figure 2.1 shows the histograms of these p-values under the null
hypotheses. As expected, all of the histograms are heavily skewed right, indicating the p-
values’ invalidity. The combined subgroup p-values are slightly less skewed, suggesting that
they are, in some sense, “less invalid” than the Experiment 1 subgroup p-values.
On the other hand, the posterior predictive p-value appears valid — in fact, conservative
— in terms of type I error (see Figure 2.2). In other words, when the null hypothesis
is true, the posterior predictive p-value rejects it less often than indicated by the nominal
significance level. Such conservatism often arises when multiply imputing missing data under
a null hypothesis (see Rubin 1998) and seems to become more extreme when the proportion
of missing data is large.
Table 2.5 displays simulation results, comparing the type I error rates based on the
Experiment 1, combined, and posterior predictive subgroup p-values.
Type I Error Rate at α = .05
Subgroup p-value Null Hypothesis A Null Hypothesis B
Experiment 1 10.3% 12.3%
Combined (Experiments 1 and 2) 8.7% 8.0%
Posterior predictive 2.0% 2.3%
Table 2.5: Type I error rates (at α = .05) of Experiment 1, combined, and posterior predictive
subgroup p-values. Based on 1,000 simulated datasets.
Conservatism under a null hypothesis is often welcome, especially in FDA contexts, pro-
vided the method exhibits sufficient power under reasonable alternative hypotheses; simula-
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Figure 2.1: Empirical distributions of Experiment 1 (top) and combined (Experiments 1 and
2; bottom) subgroup p-values under the null hypotheses described in Table 2.4. Based on
1,000 simulated datasets.
tions show this to indeed be the case. Under the alternative hypotheses described in Table
2.4, the method has substantial power, rejecting the null hypothesis at α = .05 in 21%
and 69% of replications under Alternative Hypotheses A (5% treatment effect) and B (10%
treatment effect), respectively. Figure 2.3 displays the histograms of posterior predictive
p-values under these alternative hypotheses. We also note that in the motivating example
from Section 2.2, pre-experiment sample size calculations aimed to capture 80% power at
α = .05 assuming larger treatment effects of 15–20%; according to simulations, our method
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Figure 2.2: Empirical distributions of posterior predictive p-values under the null hypotheses
described in Table 2.4. Based on 1,000 simulated datasets.
achieves over 95% power when generating data with such large effects.
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Figure 2.3: Empirical distributions of posterior predictive p-values under the alternative
hypotheses described in Table 2.4. Based on 1,000 simulated datasets.
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2.6 Conclusion
We have presented a randomization-based approach for generating valid posterior predictive
p-values for partially post-hoc subgroups. We have also demonstrated that the resulting
p-values have substantial power under reasonable alternative hypotheses. In the artificial
example provided, the multiple imputation of the missing Experiment 2 treatment potential
outcomes is facilitated by a conjugate model assuming independence between the subgroups.
Such independence may not always be plausible. For instance, only two covariates — ef-
fusion and polyarticular pain — defined the Durolane subgroup; thus, subgroup patients
could and did share other covariate values with non-subgroup patients. The augmented
framework then requires an imputation model that relates covariates to the outcomes, e.g.,
Bayesian logistic regression, under the null hypothesis. The missing Experiment 2 treatment
potential outcomes are again multiply-imputed according to their posterior predictive distri-
bution, which can be empirically constructed using Markov Chain Monte Carlo techniques.
More generally, our randomization-based approach applies to randomized experiments with
nuisance unknowns; examples of such unknowns include missing compliance statuses (see
Chapter 3) as well as missing outcome data from patients who exist in reality (as opposed
to existing only in the augmented framework).
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Chapter 3
More Powerful Multiple Testing in
Randomized Experiments with
Non-Compliance
Lee, Miratrix, and Pillai (submitted)
3.1 Introduction
The United States Job Training Partnership Act (JTPA) Study was a randomized exper-
iment in the 1980s designed to measure the effects of a national, publicly-funded training
program. Participants randomly assigned to the treatment group were eligible to receive
JTPA services, while participants randomly assigned to the control group were barred from
JTPA services for 18 months. Only about 2/3 of the treatment participants, however, ac-
tually enrolled and received any JTPA services; the other 1/3 failed to comply with their
treatment assignment. Furthermore, because of the fluid nature of the participants’ employ-
ment, researchers were interested in measuring JTPA effects across several time periods after
random assignment, including the in-training period and the first and second post-program
years. Analyzing such data requires addressing two substantial concerns: (i) due to non-
compliance, the effects of treatment assignment are not equivalent to the effects of treatment
receipt, and (ii) conducting tests for multiple time periods without appropriate adjustments
may lead to an inflated type I error rate. In this chapter, we outline an analysis method that
addresses both concerns while maintaining reasonable power to detect treatment effects.
When units in randomized experiments fail to comply with their random assignment,
inference for the effects of treatment receipt, rather than of assignment alone, becomes less
straightforward. Intention-to-treat (ITT) analyses, which ignore treatment receipt, may have
low power when assignment alone has no effect on the experimental outcome. In order to
address this loss of power, Rubin (1998) introduced randomization-based posterior predictive
p-values for the complier average causal effect (CACE) and showed through simulation that
(i) they are valid p-values in terms of type I error, and (ii) they have higher power than ITT p-
values under reasonable alternative hypotheses. This framework follows the general approach
for Bayesian causal inference in randomized experiments with non-compliance outlined by
Imbens and Rubin (1997). Both pieces of work rely on the multiple imputation (Rubin
1987) of missing compliance statuses; separating the experimental units into principal strata
(Frangakis and Rubin 2002) based on compliance behavior aids inference for the desired
causal effect. We use these tools in our approach but adapt them for simultaneous testing
of multiple outcomes and subgroups.
Multiple testing issues are common in randomized experiments because multiple out-
comes and subgroups of interest are often measured and analyzed for possible effects. Tra-
ditionally, practitioners have applied Bonferroni corrections to sets of p-values in order to
control their familywise error rate (FWER), i.e., the rate at which at least one type I error
is made, in a straightforward manner. Bonferroni corrections, however, tend to be overly
conservative, especially when those p-values are correlated (Westfall and Young 1989). Such
conservatism has led many applied researchers to avoid Bonferroni corrections and abandon
multiple comparisons adjustments altogether (Cabin and Mitchell 2000; Nakagawa 2004; Per-
neger 1998; Rothman 1990). Other avenues exist; randomization-based procedures can pro-
vide greater power while maintaining the FWER by accounting for correlated tests. Brown
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and Fears (1981) and Westfall and Young (1989) first introduced permutation-based multiple
testing adjustments, though they did not explicitly motivate them using randomized assign-
ment mechanisms. Randomization-based procedures are additionally appealing because they
do not require any assumptions about the underlying distribution (here, joint) of the data.
Furthermore, recent increases in computational power have helped such procedures become
more tractable and gain popularity (Good 2005).
In this chapter, we connect and extend methodological ideas to appropriately handle
both non-compliance and multiple testing in randomized experiments. We build up to this
combined approach in stages. In Section 3.2, we elucidate the method proposed by Rubin
(1998) for evaluating meaningful causal effects in the presence of non-compliance. In Sec-
tion 3.3, we extend the ideas of Westfall and Young (1989) to fully randomization-based
multiple comparisons adjustments and propose such adjustments as a straightforward yet
more powerful alternative to Bonferroni corrections. In Section 3.4, we merge the notions
of non-compliance and multiple testing, and outline a combined method of analysis that
demonstrates power advantages from both perspectives. In each of Sections 3.2–3.4, we
empirically show the benefits of the described methods through a series of simulated exper-
iments. In Section 3.5, we apply traditional methods and our combined method to JTPA
data to evaluate the program’s effects on employment rate by time period. We illustrate
how the methods lead to different conclusions regarding the significance of estimated JTPA
effects. Section 3.6 concludes.
3.2 Experiments with Non-compliance
3.2.1 Non-compliance as a missing data problem
Suppose we have a randomized experiment with N units, indexed by i, with observed co-
variates Xi, randomly assigned to control or active treatment. Let Zi be a binary indicator
for assignment to active treatment, and let Di(z) be a binary indicator for receipt of active
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treatment under assignment z. A unit’s compliance behavior Ci is defined by the pair of po-
tential outcomes (Neyman 1923; Rubin 1974) (Di(0), Di(1)); this notation is sufficient under
the stable unit treatment value assumption (Rubin 1980, 1986), which asserts no interference
between experimental units, as well as two well-defined outcomes. Each unit then belongs
to one of four possible compliance strata:
• Compliers (Ci = c), who receive their treatment assignment: (Di(0), Di(1)) = (0, 1).
• Never-takers (Ci = nt), who never receive the active treatment: (Di(0), Di(1)) = (0, 0).
• Always-takers (Ci = at), who always receive the active treatment:
(Di(0), Di(1)) = (1, 1).
• Defiers (Ci = d), who receive the opposite of their treatment assignment:
(Di(0), Di(1)) = (1, 0).
If non-compliance is one-sided — i.e., units assigned to control are prohibited from re-
ceiving the active treatment — then Di(0) = 0 for all i. In such settings, always-takers
and defiers do not exist, and two possible strata are left: compliers and never-takers. Real-
world scenarios involving one-sided non-compliance include many clinical trials, in which
new drugs are unavailable to control patients, and some job training experiments, in which
training programs and additional services are unavailable to the control group.
In many practical settings, researchers are most interested in the compliers because the
effect of treatment assignment is synonymous with the effect of treatment receipt for those
units. Strata membership, however, can never be fully determined for all units because
they depend on the two potential outcomes of D, one of which is missing (i.e., unobserved).
Membership can, on the other hand, be partially determined based on the observed potential
outcome, Dobsi . Table 3.1 outlines the possible compliance strata based on units’ observed
treatment assignment and receipt. An example “Science” table (Rubin 2005) under one-
sided non-compliance and its observed values under a particular assignment are shown in
Table 3.2.
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Assignment Receipt Possible Ci Values
Zi D
obs
i One-sided Non-compliance Two-sided Non-compliance
0 0 c, nt c, nt
0 1 – at, d
1 0 nt nt, d
1 1 c c, at
Table 3.1: Units’ possible compliance strata based on observed treatment assignment and
receipt.
D(z) Compliance Y (z) Assignment D(z) Compliance Y (z)
Unit Xi Di(0) Di(1) Ci Y (0) Y (1) Zi Di(0) Di(1) Ci Yi(0) Yi(1)
1 X1 0 0 nt Y1(0) Y1(1) 0 0 ? ? Y
obs
1 ?
2 X2 0 1 c Y2(0) Y2(1) 1 0 1 c ? Y
obs
2
3 X3 0 1 c Y3(0) Y3(1) 1 0 1 c ? Y
obs
3
4 X4 0 0 nt Y4(0) Y4(1) 1 0 0 nt ? Y
obs
4
. . . . . . . . .
N XN 0 1 c YN(0) YN(1) 0 0 ? ? Y
obs
N ?
Table 3.2: An example Science table under one-sided non-compliance (left) and its corre-
sponding observed and unobserved values under a particular assignment (right).
Because strata memberships are not fully observed, uncertainty with respect to complier-
specific effects stems from the missing compliance statuses (i.e., D potential outcomes) in
addition to the missing Y potential outcomes. One approach to handling the additional
uncertainty is to, in a Bayesian framework, view the missing compliance statuses as random
variables. By multiply imputing the missing compliance statuses, e.g., according to a dis-
tributional model, they can be “integrated out,” and we can make inference specific to the
compliers.
3.2.2 Randomization-based posterior predictive p-values
As described by Meng (1994), a posterior predictive p-value can be viewed as the poste-
rior mean of a classical p-value, averaging over the posterior distribution of nuisance factors
(e.g., missing compliance statuses) under the null hypothesis. Rubin (1998) introduced a
randomization-based procedure, which we expound on here, for obtaining posterior predic-
tive p-values for estimated complier-only effects. One posterior predictive p-value is the
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average of many p-values calculated from multiple “compliance-complete” datasets with im-
puted compliance statuses; for each compliance-complete dataset, the p-value is obtained
through a randomization test (Fisher 1925, 1935). Within one randomization test, however,
calculations of the test statistic do not use all of the compliance data; rather, they use only
the compliance data that would have actually been observed under particular hypothetical
randomizations. Though implied, this step of re-observing the data is not explicitly stated
by Rubin (1998); we place it in Step 5 of the procedure below for emphasis.
In this section, we assume a single outcome for simplicity. The procedure for obtaining
a randomization-based posterior predictive p-value is as follows:
1. Choose a test statistic and calculate its observed value.
Choose a test statistic, T , to estimate an effect on the outcome, Y . Examples include
the maximum-likelihood estimate (MLE) of CACE or the posterior median of CACE,
given the observed compliance statuses and potential outcomes, under the exclusion
restriction (see Angrist et al. 1996; Imbens and Rubin 1997). Unlike discrepancy vari-
ables (Meng 1994), which may depend on unobserved factors (e.g., missing compliance
statuses), statistics must be functions of only the observed data. Calculate T on the
observed data to obtain T obs.
for m : 1 to M do
2. Impute missing compliance statuses.
Impute the missing compliance statuses, drawing once from their posterior predictive
distribution according to a compliance model that assumes the null hypothesis.
3. Impute missing potential outcomes.
Impute the missing Y potential outcomes under the sharp null hypothesis. Under the
typical sharp null hypothesis of zero treatment effect, the missing potential outcome
for unit i is imputed exactly as Y obsi .
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4. Draw a random hypothetical assignment.
Draw a random hypothetical assignment vector according to the assignment mecha-
nism.
5. Re-observe the data.
Treating the imputed compliance statuses, imputed potential outcomes, and hypo-
thetical assignment vector from Steps 2–4 as true, create a corresponding hypothetical
observed dataset by masking the potential outcomes and compliance statuses that
would not have been observed under the hypothetical assignment.
6. Calculate the test statistic on these data.
Calculate T on the hypothetical observed data to obtain T hyp. Record whether this
statistic is at least as extreme as T obs.
end for
7. Calculate the posterior predictive p-value.
The posterior predictive p-value for the null hypothesis with respect to T equals the
proportion of the M imputation-randomization sets for which T hyp is as extreme as or
more extreme than T obs.
Rubin (1998) discusses several commonly used statistics for evaluating complier causal
effects, only some of which tend to estimate CACE and thus provide suitable power against
appropriate alternative hypotheses. As is commonly done in non-compliance literature, we
assume the exclusion restriction (i.e., we assume that treatment assignment has no effect
on the outcomes of never-takers and always-takers) for test statistic calculations throughout
this paper. Such an assumption is not necessary and does not affect the validity of the
randomization test, but it does facilitate more precise estimation of CACE when true (see
Imbens and Rubin 1997) and is often reasonable.
The imputation in Step 2 is performed probabilistically, using the missing statuses’ null
posterior predictive distribution, given X,Z,Dobs, and Y obs. (Some test statistics, such as the
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posterior median of CACE, may be computed by multiply imputing the missing compliance
statuses. This would be a separate imputation from the one described in Step 2 above. If
the test statistic calculation itself involves imputation, such imputation does not need to,
and usually does not, assume the null hypothesis.) The repetition of Steps 2–6 is intended
to reflect the uncertainty of estimation resulting from the missing compliance statuses; M is
a large number (e.g., 10, 000) that controls the Monte Carlo integration error.
Under the null hypothesis, Y is not affected by assignment to or receipt of the active
treatment; it is therefore treated like a covariate in the imputation model. Even in the
absence of other covariates (X), Y alone may still be successful in stochastically identifying
the missing compliance statuses, thus providing tests of CACE with power over ITT tests
(see Section 3.2.3). When additional covariates that affect compliance status supplement
Y in the imputation model (e.g., in a Bayesian generalized linear model), the compliance
identification tends to sharpen, providing CACE tests with greater power.
In settings with one-sided non-compliance, only the compliance statuses of units assigned
to the control group are missing. Let ωc be the super-population proportion of compliers,
and let η = (ηc, ηn) be the parameters that govern the outcome distributions of compli-
ers and never-takers, respectively. Note that under the null hypothesis, these are only two
outcome distributions; units within a compliance stratum have the same outcome distribu-
tions, regardless of their treatment assignment. The posterior predictive distribution of the
missing compliance statuses can be obtained using a two-step data augmentation algorithm
(Tanner and Wong 1987). Using the current (or initial, if starting the algorithm) values of
the parameters, the missing compliance statuses are drawn according to Bayes’ rule:
P (Ci = c|Y obsi , Xi, Zi = 0, Dobsi = 0, ωc,η) =
ωcgc(Y
obs
i ; ηc)
ωcgc(Y obsi ; ηc) + (1− ωc)gn(Y obsi ; ηn)
, (3.1)
where gc(y; ηc) and gn(y; ηn) are the outcome probabilities (or densities) of y for compliers and
never-takers, respectively. Once the missing compliance statuses are drawn, new parameter
values are drawn from their compliance-complete-data posterior distributions. These two
steps are alternated until distributional convergence. After convergence, the draws of the
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missing compliance statuses can be treated as posterior predictive imputations. Obtaining
posterior draws of parameters — and consequently, posterior predictive draws of the missing
compliance statuses — may be more straightforward if models are conjugate, e.g., Beta-
Binomial or Dirichlet-Multinomial models (see Section 3.2.3).
For each imputation of the missing compliance statuses, a randomization test (here in-
volving only one random hypothetical assignment for computational efficiency) is performed
in Steps 3–6. Because p-values are defined as conditional probabilities given that the sharp
null hypothesis is true, the imputation of Y potential outcomes in Step 3 must occur under
this hypothesis. Table 3.3 shows the observed values of the Science table from Table 3.2,
with the Y potential outcomes imputed under the sharp null hypothesis of zero treatment
effect. For computational efficiency, Step 3 can be performed just once (before the loop)
because this imputation is deterministic.
Assignment D(z) Compliance status Y (z)
Unit Xi Zi Di(0) Di(1) Ci Yi(0) Yi(1)
1 X1 0 0 ? ? Y
obs
1 (Y
obs
1 )
2 X2 1 0 1 c (Y
obs
2 ) Y
obs
2
3 X3 1 0 1 c (Y
obs
3 ) Y
obs
3
4 X4 1 0 0 nt (Y
obs
4 ) Y
obs
4
. . . . . .
N XN 0 0 ? ? Y
obs
N (Y
obs
N )
Table 3.3: The observed values of the Science table from Table 3.2, with the missing Y po-
tential outcomes imputed under the sharp null hypothesis of zero treatment effect. Imputed
Y potential outcomes are in parentheses.
The random draw of a hypothetical assignment vector in Step 4 depends on the spe-
cific assignment mechanism used in the experiment, e.g., complete randomization or block
randomization. A seemingly alternative procedure to the one described above switches the
order of Steps 2 and 4, such that the hypothetical assignment vector is drawn first, and the
missing compliance statuses are imputed second. This alternative procedure, however, is
exactly equivalent to the one described above because the imputation of the missing compli-
ance statuses under the null hypothesis is influenced by Z only through Cobs. Because Cobs
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is fixed by the actual observed data, reversing the order of Steps 2 and 4 does not affect the
overall inferential procedure. Intuitively, we can consider the posterior predictive p-value as
a double integral over the missing compliance statuses and the randomization; switching the
order of integration does not affect the result.
3.2.3 Illustrative simulations with non-compliance
Consider this modified example from Rubin (1998): suppose a completely randomized
double-blind experiment is conducted to investigate the effect of a new drug (provided in
addition to standard care) versus standard care alone on Y , which measures the severity of
patients’ heart attacks in the year following treatment. Y is ordinal, taking on values of 0,
1, and 2 (no, mild, and severe attacks, respectively). We assume that all of the patients
survive through the year. We also assume one-sided non-compliance, so our experiment has
two groups of patients: compliers and never-takers.
In our simulation, we randomly select N = 1000 units from a super-population of 10%
compliers and 90% never-takers; the compliers tend to be healthier than the never-takers.
We randomly assign N/2 = 500 units to control and N/2 units to active treatment, observ-
ing only the compliance statuses of units assigned to active treatment. For each unit, we
generate an observed Multinomial outcome, Y obsi , according to the specified treatment effect
hypothesis. Simulation details are provided in Appendix A.1.
Using the simulated observed data, we calculate two test statistics: (i) the ITT statistic,
and (ii) the MLE of CACE under the exclusion restriction. We then calculate randomization-
based posterior predictive p-values for both test statistics, as described in Section 3.2.2, under
the null hypothesis of zero treatment effect. (For the multiple imputation of the missing
compliance statuses, we place conjugate Beta(1, 1) priors on the parameters governing the
complier and never-taker outcome distributions.) To evaluate the frequency characteristics
of the posterior predictive p-values, we run 1,000 replications of the data simulation and
p-value procedures. Under the null hypothesis, p-values for the two statistics both appear
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valid in terms of type I error; their empirical distributions are approximately uniform. At
the α = .05 level, tests on ITT and CACE reject the null hypothesis in 4.5% and 4.1% of
simulations, respectively. Under the alternative hypothesis, tests based on the CACE are
more powerful (see Figure 3.1), with tests on ITT and CACE rejecting the null hypothesis in
16.7% and 25.2% of simulations, respectively, at α = .05. In a general setting, the magnitude
of the power gain from CACE depends on the proportion of compliers, the magnitude of the
treatment effect, and the α level.
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Figure 3.1: Joint distribution of 1,000 posterior predictive p-values for ITT and CACE
estimates under the alternative hypothesis. Tests for CACE are more powerful because
p-values for CACE tend to be lower.
3.3 Experiments with Multiple Testing
3.3.1 Randomization-based multiple comparisons adjustments
Suppose we have data from a randomized experiment with J estimands and are interested in
testing whether the active treatment has any non-null effects. The desire for J estimands may
result, for example, from multiple outcomes per unit or from multiple, potentially overlapping
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subgroups of units. Brown and Fears (1981) and Westfall and Young (1989) first proposed
permutation-based multiple comparisons adjustments, with the latter showing that such ad-
justments outperform traditional (e.g., Bonferroni) adjustments in terms of power. They did
not, however, explicitly motivate their methods using randomized assignment mechanisms
and joint randomization distributions. Furthermore, they assumed specific models that fa-
cilitated the calculation of nominal (unadjusted) p-values and implicitly assumed completely
randomized assignments throughout.
Here we extend their ideas to a fully randomization-based procedure for multiple com-
parisons adjustments. In contrast to the aforementioned work, our procedure is connected
to — and directly motivated by — the actual randomized assignment mechanism used in
the experiment; in addition, both the nominal and adjusted p-values in our procedure are
randomization-based, so we do not require any assumptions about the underlying distribu-
tion of the data. We calculate fully randomization-based adjusted p-values as follows:
1. Choose test statistics and calculate their observed values.
Choose test statistics, (T1, . . . , TJ), and calculate (T
obs
1 , . . . , T
obs
J ) on the observed data.
2. Impute missing potential outcomes.
Impute the missing potential outcomes under the sharp null hypothesis.
3. Calculate nominal p-values for the observed test statistics.
For j = 1, . . . , J , calculate the randomization-based p-value for T obsj by repeatedly
(i) drawing a random hypothetical assignment vector according to the assignment
mechanism, and (ii) calculating the test statistic, T hypj , for the corresponding hypo-
thetical observed data. The nominal, marginal randomization-based p-value for T obsj
(j = 1, . . . , J) equals the proportion of T hypj values that are as extreme as or more
extreme than T obsj .
for m′ : 1 to M ′ do
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4. Calculate nominal (marginal) p-values for hypothetical test statistics.
Draw a random hypothetical treatment assignment according to the assignment
mechanism and calculate test statistics (T hyp1 , . . . , T
hyp
J ) on the corresponding hy-
pothetical observed data. Calculate a nominal randomization-based p-value for each
T hypj and record the minimum of the p-values.
end for
5. Obtain the joint randomization distribution of the nominal p-values.
For large M ′, the repetitions of Step 4 appropriately capture the joint randomization
distribution of the test statistics and thus, of the nominal p-values.
6. Calculate adjusted p-values for the observed test statistics.
The adjusted p-value (Westfall and Young 1989) for T obsj (j = 1, . . . , J) equals the
proportion of hypothetical observed datasets for which the minimum of the J nominal
p-values for (T hyp1 , . . . , T
hyp
J ) is less than or equal to the nominal p-value for T
obs
j .
For computational efficiency, the hypothetical randomizations and statistic calculations
in Step 3 can be recycled for Steps 4–5: Steps 4–5 essentially represent a translation, i.e., re-
scaling, of hypothetical test statistics — which may have different scales — into hypothetical
p-values, which share a common 0–1 scale. The procedure described above results in indi-
vidual adjusted p-values that are corrected for the FWER but are also directly interpretable
on their own.
Equivalently, to determine α-level significance, we can compare each nominal p-value to
the familywise α-level cutoff: the α-th quantile of the minimums recorded in Step 4. The
probability that no type I errors are made (i.e., that we fail to reject all J tests under the
null hypothesis) is equivalent to the probability that all J observed marginal p-values are
above the cutoff. This equals the probability that the minimum of the J observed p-values
is above the cutoff, which is 1−α by construction. Thus, the probability of at least one type
I error — the FWER — is α, as desired.
46
Randomization-adjusted p-values are more powerful than traditional Bonferroni-adjusted
p-values, especially when the correlations among the J test statistics are high, as shown by
the simulations below. Intuitively, suppose the null hypothesis is true and that we have a
large number of uncorrelated test statistics; the probability of at least one type I error is
quite high because of the number of tests being conducted. Now suppose instead that those
test statistics are highly correlated; the probability of at least one type I error is reduced
because the tests’ type I errors are likely to occur simultaneously, i.e., for the same random
assignments. In fact, if the test statistics are perfectly correlated, there is essentially only
one test being conducted, so no multiple comparisons adjustment is needed. Bonferroni
adjustments in all of these settings are the same, simply counting the number of p-values
being examined. In contrast, by utilizing the joint distribution of the nominal p-values, the
randomization-based adjustments account for the correlations among test statistics and are
less conservative.
3.3.2 Illustrative simulations with multiple testing
We follow the experimental setup from Section 3.2.3, modified to include multiple outcomes
but without non-compliance. Suppose that researchers now want to investigate the effect
of the new drug on three outcomes: Y·1, Y·2, and Y·3 (with the first subscript denoting the
participant), which measure the severity of heart attacks (defined as before) in the first,
second, and third year after treatment, respectively. We assume that all of the patients
survive through the third year, and we would like to see whether the drug has an effect on
heart attack severity at any of the three time points.
To evaluate the frequency characteristics of the adjusted randomization-based p-values,
we simulate 1,000 datasets under both null and alternative hypotheses according to each of
three outcome correlation structures: zero, partial (approximately 0.5), and perfect corre-
lation. The specific data generation processes are found in in Appendices A.2 and B. The
correlations among Yi1(z), Yi2(z), and Yi3(z) (z = 0, 1) are important; however, for a fixed
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j, the correlation between Yij(0) and Yij(1) is inconsequential to the simulation because we
only ever observe one of the potential outcomes.
For each simulated dataset, we calculate fully randomization-based adjusted p-values
and decide whether or not to reject the null hypothesis of zero treatment effects across the
three time periods at α = .05. For comparison, we also decide whether or not to reject the
null hypothesis using Bonferroni-adjusted p-values. Simulation results under both null and
alternative hypotheses are shown in Table 3.4. Without sacrificing validity under the null
hypothesis, the randomization-based adjustment displays greater power than the Bonferroni
adjustment under the alternative hypothesis, particularly for scenarios with high correlations
among outcomes.
Rejection Rate at α = .05
Null is true Alternative is true
Bonferroni Randomization-Based Bonferroni Randomization-Based
Zero correlation .042 .046 .908 .919
Partial correlation .045 .053 .787 .811
Perfect correlation .024 .045 .557 .720
Table 3.4: Proportions of multiple testing simulations in which the null hypothesis was
rejected, under various data generation processes. Based on 1,000 replications.
3.4 Experiments with Both Non-compliance and
Multiple Testing
It is natural to merge the analysis methods presented in Sections 3.2 and 3.3 — both of which
use the randomized assignment mechanism to aid inference — for experiments involving both
non-compliance and multiple testing. The results are valid familywise tests that are doubly
more powerful: more powerful than both those based on standard ITT statistics and those
using traditional multiple comparison adjustments.
Suppose again that we have data from a randomized experiment with J estimands and
that we are interested in testing whether the active treatment has any non-null effects.
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However, not all units comply to their treatment assignments; assume for simplicity that
non-compliance is one-sided. In Section 3.2, Table 3.2 displays the observed values of a
Science table with two Y potential outcomes — one observed and one missing — for each
unit. Here, Table 3.5 shows the corresponding observed values of a Science table with
multiple estimands resulting from J = 3 outcomes of interest. Each unit has six potential
outcomes, only three of which are observed; the other three are missing. Within unit i, we
observe the same member of (Yij(0), Yij(1)) for each outcome j, e.g., if we observe Yi1(1),
then we also observe Yi2(1) and Yi3(1).
Assignment D(z) Compliance status Y·1(z) Y·2(z) Y·3(z)
Unit Xi Zi Di(0) Di(1) Ci Yi1(0) Yi1(1) Yi2(0) Yi2(1) Yi3(0) Yi3(1)
1 X1 0 0 ? ? Y
obs
11 ? Y
obs
12 ? Y
obs
13 ?
2 X2 1 0 1 c ? Y
obs
21 ? Y
obs
22 ? Y
obs
23
3 X3 1 0 1 c ? Y
obs
31 ? Y
obs
32 ? Y
obs
33
4 X4 1 0 0 nt ? Y
obs
41 ? Y
obs
42 ? Y
obs
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. . . . . . . . .
N XN 0 0 ? ? Y
obs
N1 ? Y
obs
N2 ? Y
obs
N3 ?
Table 3.5: Observed and unobserved values of the Science table from Table 3.2, now with
three outcomes of interest. Missing (unobserved) data are denoted by question marks.
In experiments with non-compliance and multiple testing, obtaining valid and doubly
more powerful familywise tests involves (i) calculating (nominal) posterior predictive p-values
for CACE according to the procedure in Section 3.2, and (ii) calculating adjusted posterior
predictive p-values using the joint randomization distribution of the nominal p-values, ac-
cording to the procedure in Section 3.3. Intuitively, this combined method of analysis is
preferable because Steps (i) and (ii) provide power gains through distinct and unrelated
mechanisms, and neither sacrifices validity in terms of type I error. For the J estimands, we
expect each individual (nominal) CACE p-value to be more powerful than its ITT counter-
part based on the arguments in Section 3.2. Furthermore, given a set of J nominal p-values,
we expect randomization-adjusted p-values using the nominal p-values’ joint randomization
distribution to be more powerful than Bonferroni-adjusted p-values, as argued in Section 3.3.
Naturally, adjusting more powerful nominal p-values in a more powerful manner results in
doubly more powerful adjusted p-values. The full procedure is detailed below:
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1. Choose test statistics and calculate their observed values.
Choose test statistics, (T1, . . . , TJ), and calculate (T
obs
1 , . . . , T
obs
J ) on the actual ob-
served data.
for i : 1 to M do
2. Impute missing compliance statuses.
Impute the missing compliance statuses, drawing once from their posterior predictive
distribution according to a compliance model that assumes the null hypothesis.
3. Impute missing potential outcomes.
Impute all of the missing (Y1, . . . , YJ) potential outcomes under the sharp null hy-
pothesis.
4. Draw a random hypothetical assignment.
Draw a random hypothetical assignment vector according to the assignment mecha-
nism.
5. Re-observe the data.
Treating the imputed compliance statuses and potential outcomes and the hypothet-
ical assignment vector as true, create a corresponding hypothetical observed dataset
by masking the potential outcomes and compliance statuses that would not have been
observed under the hypothetical assignment.
6. Calculate test statistics on the hypothetical observed data.
Calculate (T1, . . . , TJ) on the hypothetical observed data to obtain (T
hyp
1 , . . . , T
hyp
J ).
For j = 1, . . . , J , record whether T hypj is at least as extreme as T
obs
j .
end for
7. Calculate nominal (marginal) posterior predictive p-values for the observed
test statistics.
For j = 1, . . . , J , the nominal (marginal) posterior predictive p-value for the null hy-
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pothesis with respect to the test statistic Tj equals the proportion of the M imputation-
randomization sets created by Steps 2–6 for which T hypj is as extreme as or more extreme
than T obsj .
8. Calculate nominal posterior predictive p-values for hypothetical test statis-
tics and obtain the joint randomization distribution of the nominal posterior
predictive p-values.
For each of theM imputation-randomization sets, translate the hypothetical test statis-
tics (T hyp1 , . . . , T
hyp
J ) into hypothetical nominal posterior predictive p-values using pro-
portions similar to the one described in Step 7. This step is a computationally efficient
way of obtaining the joing distribution of hypothetical test statistics on a common
p-value scale, analogous to Steps 4–5 from the procedure in Section 3.3. Record the
minimum of each set of nominal p-values.
9. Calculate adjusted posterior predictive p-values for the observed test statis-
tics.
The adjusted posterior predictive p-value for T obsj (j = 1, . . . , J) equals the proportion
of the M imputation-randomization sets for which the minimum of the J nominal
posterior predictive p-values for (T hyp1 , . . . , T
hyp
J ) is less than or equal to the nominal
(marginal) posterior predictive p-value for T obsj .
Under the null hypothesis, the outcomes Y·1, . . . , Y·J inform the multiple imputation of
the missing compliance statuses. Posterior predictive imputations of the missing compliance
statuses can be generated using a data augmentation algorithm similar to the one described
in Section 3.2, with Equation 3.1 modified to use the joint set of J observed outcomes.
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3.4.1 Illustrative simulations with both non-compliance and
multiple testing
Again consider the heart treatment example from Sections 3.2.3 and 3.3.2: we would like to
see whether the active treatment has an effect on heart attack severity at any of the three
time points after treatment. In these simulations, we assume one-sided non-compliance,
with N = 1000 units randomly sampled from a super-population of 10% compliers and 90%
never-takers. The data generation processes are described in Appendices A.3 and B.
For each simulated dataset, four familywise tests are conducted. Two of the tests use the
ITT test statistic, one with the Bonferroni correction and the other with the randomization-
based multiple comparisons adjustment. The other two tests use the MLE of CACE (under
the exclusion restriction) as the test statistic, one with the Bonferroni correction and the
other with the randomization-based adjustment. Table 3.6 displays proportions of simula-
tions in which the null hypothesis was rejected, based on 500 replications.
Rejection Rate at α = .05
ITT CACE
Null is true Bonferroni Randomization-Based Bonferroni Randomization-Based
Zero correlation .036 .042 .022 .024
Partial correlation .022 .036 .018 .030
Perfect correlation .016 .056 .008 .040
ITT CACE
Alternative is true Bonferroni Randomization-Based Bonferroni Randomization-Based
Zero correlation .198 .222 .240 .260
Partial correlation .114 .148 .178 .206
Perfect correlation .092 .184 .142 .256
Table 3.6: Proportions of simulations in which the null hypothesis was rejected, under various
data generation processes. Based on 500 replications.
Under the null hypothesis, all four familywise tests appear valid in terms of type I er-
ror. The randomization-based tests have the rejection rates closest to the nominal rejection
rates. As expected, the Bonferroni-adjusted tests are conservative, especially when cor-
relation among outcomes is high. In such settings, there are, in a sense, fewer possible
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effects to detect, and randomization-adjusted rejection rates are much higher relative to
their Bonferroni-adjusted counterparts.
Under alternative hypotheses, the CACE tests generally have higher power, i.e., higher
rejection rates, than the ITT tests. In addition, the randomization-based tests outperform
their Bonferroni counterparts, especially when correlation among outcomes is high. In our
simulations, CACE tests with randomization-based multiple comparisons adjustments have
30% to 175% higher relative power than traditional Bonferroni ITT tests. In a particular
experimental setting, the magnitude of the power gain from the combined analysis method
depends on the compliance rate, the magnitude of the treatment effect, the α level, and the
correlation of the multiple test statistics.
3.5 The National Job Training Partnership Act Study
Title II of the United States Job Training Partnership Act (JTPA) of 1982 funded employ-
ment training programs for economically disadvantaged residents (Bloom et al. 1997; Abadie
et al. 2002). To evaluate the effectiveness of those training programs, the National JTPA
Study conducted a randomized experiment through 16 local administration areas involving
a total of around 20,000 participants who applied for JTPA services from November 1987 to
September 1989 (W.E. Upjohn Institute for Employment Research 2013). Treatment group
participants were eligible to receive JTPA services, while control group participants were
ineligible to receive JTPA services for 18 months. Not every participant assigned to the
treatment group actually enrolled and received JTPA services.
3.5.1 The data
Monthly employment outcomes were recorded for 30 months after assignment through follow-
up surveys and administrative records from state unemployment insurance agencies. Re-
searchers were interested in measuring JTPA effects across three time periods represent-
53
ing various stages of training and employment: months 1–6 (after assignment), the period
when most JTPA enrollees were in the program; months 7–18, approximately the first post-
program year; and months 19–30, approximately the second post-program year (Bloom et al.
1997).
Bloom et al. (1997)’s original JTPA report evaluates effects on average income but does
not explicitly address the large portion of zero-income (i.e., unemployed) participants. Al-
though the report describes effects by subperiod as well as by various participant subgroups,
it fails to mention or employ any multiple comparisons adjustments. Here we focus on
JTPA’s effects on employment status and use gender as our only background covariate; this
facilitates standard, non-controversial modeling choices (see Section 3.5.2) and allows us to
highlight our methodological contributions rather than discuss the sensitivity of our results
to various, possibly complicated modeling decisions. Our methods can be extended to eval-
uate effects on other outcome variables, such as income and wages, provided that we outline
a reasonable imputation model (Zhang et al. 2009).
We would like to evaluate whether JTPA had an effect on employment status for any of
the three time periods. Because employment characteristics often differ by gender, we exam-
ine JTPA effects for the three time periods by gender, for a total of six gender-time groups.
For illustrative purposes, we restrict our study population to adults who had obtained a high
school or GED diploma (7,445, or 66.4%, of the 11,204 total adults in the original JTPA
study) and assume complete randomization (with an approximate 2 : 1 treatment-to-control
assignment ratio) of the participants, ignoring the local administration structure because of
the limitations of the available data.
Of the 5,009 participants assigned to the treatment group, 3,316 (66.2%) subsequently
received JTPA training. Although the study protocol barred participants assigned to the
control group from receiving JTPA services for 18 months, 41 (1.7%) of 2,436 adults in the
control group did in fact receive services within that time frame. To create a simpler setting
with true one-sided non-compliance, we discard these 41 participants (0.6% of the 7,445 total
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adults in our study) with the belief that their inclusion would have a negligible influence on
the resulting inference.
Given two genders and three time periods, we have six complier-focused estimands in
total, each one representing the difference in employment proportions within a particular
gender-time group when receiving versus not receiving JTPA services. Two summaries of
the observed data are provided in Figure 3.2 and Table 3.7. Figure 3.2 shows observed
employment proportions across the six gender-time groups by observed compliance status.
Within every group, observed compliers are employed at a higher rate than observed never-
takers. Participants with unobserved compliance statuses (i.e., those assigned to control)
are a mixture of compliers and never-takers, and tend to be employed at a rate in between
the rates for observed compliers and observed never-takers.
Female, Months 1−6 Female, Months 7−18 Female, Months 19−30 Male, Months 1−6 Male, Months 7−18 Male, Months 19−30
Observed never−takers
Observed compliers
Unobserved compliance statuses
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Figure 3.2: Observed employment proportions for JTPA participants by compliance status
across the six gender-time groups.
Table 3.7 displays observed employment proportions across the gender-time groups ac-
cording to both treatment assignment and treatment receipt, with the corresponding com-
pliance compositions. We see that participants who received JTPA services, all of whom are
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Observed Employment Proportions
Assigned Control Assigned Treatment
Ci ∈ {c, nt}, Zi = 0 Ci ∈ {c, nt}, Zi = 1
Female, Months 1–6 .709 .723
Female, Months 7–18 .767 .800
Female, Months 19–30 .694 .714
Male, Months 1–6 .765 .785
Male, Months 7–18 .798 .789
Male, Months 19–30 .715 .712
Received Control Received Treatment
(Ci ∈ {c, nt}, Zi = 0) or (Ci = nt, Zi = 1) Ci = c, Zi = 1
Female, Months 1–6 .708 .730
Female, Months 7–18 .764 .818
Female, Months 19–30 .677 .743
Male, Months 1–6 .740 .828
Male, Months 7–18 .769 .823
Male, Months 19–30 .683 .753
Table 3.7: Observed employment proportions across the six gender-time groups according
to both assignment to and receipt of JTPA services.
compliers, tend to be employed at a higher rate than participants who were merely assigned
to the treatment group (a mixture of compliers and never-takers), corroborating the findings
in Figure 3.2 and suggesting that CACE statistics may lead to more significant estimated
effects. In addition, we observe that participants who did not receive JTPA services — in-
cluding any participants assigned to control as well as the never-takers assigned to JTPA —
are employed at a lower rate than just the participants assigned to control. This inequality
is intuitive because the observed never-takers are shown in Figure 3.2 to be employed at a
lower rate than the assigned control group.
3.5.2 Imputation model for CACE
To test the null hypothesis of zero effects using the CACE statistic specified in Section 3.2,
we must specify an imputation model for the missing compliance statuses. Let Xi and Yi
denote the gender and the length-3 vector of employment outcomes (across the three time
periods) of participant i. The three elements of Yi are binary, so there are 2
3 = 8 possible
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values of Yi; we model Y as a Multinomial random variable with eight categories. Let
ωc be the super-population proportion of compliers, and let η = (ηfc, ηfn, ηmc, ηmn) be the
parameters that govern the outcome distributions of female compliers, female never-takers,
male compliers, and male never-takers, respectively. Under the null hypothesis, these are
the only four outcome distributions because we disregard treatment assignment. We place
a conjugate Beta(1,1) prior on ωc and independent conjugate Dirichlet(1) priors on the four
η parameters, where 1 is a length-8 vector of 1’s.
Conditional on η and a participant’s gender and compliance status, the natural outcome
distribution under the null hypothesis is:
Y obsi |Xi = x,Ci = q,η ∼ Multinomial(1, ηxq).
Note that we do not assume that the three employment outcomes are independent; this
model is fully non-parametric for the joint distribution of the three outcomes. The posterior
distributions of ωc and η are informed by the outcomes of the participants with observed
compliance statuses, i.e., those assigned to active treatment, and remain Beta and Dirichlet,
respectively. For each gender x and compliance status q, write the Multinomial probability
vector as
ηxq = (pixq1, ..., pixq7, 1− pixq1 − . . .− pixq7).
Let
gxq(y; ηxq) = pi
I{y=(0,0,0)}
xq1 pi
I{y=(0,0,1)}
xq2 . . . (1− pixq1 − . . .− pixq7)I{y=(1,1,1)}
denote the probability of outcome y for participants of gender x and compliance status
q. Then, given a posterior draw of (ωc,η), the missing compliance statuses are imputed
probabilistically according to Bayes’ rule:
P (Ci = c|Y obsi , Xi = x, Zi = 0, ωc,η) =
ωcgxc(Y
obs
i ; ηxc)
ωcgxc(Y obsi ; ηxc) + (1− ωc)gxn(Y obsi ; ηxn)
. (3.2)
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3.5.3 Results and analysis
The observed values of the ITT and CACE statistics — i.e., the estimated effects of JTPA
assignment and of receipt, respectively — are shown in the second column of Table 3.8. As
we expect, the observed CACE values have larger magnitudes; the estimated ITT effects are
diluted toward zero by the never-takers, who do not receive any treatment benefit. Because
ITT = ωc ∗CACE + (1−ωc) ∗ 0, the estimated ITT effects are diluted by a proportion equal
to one minus the compliance rate. Due to the random treatment assignment, we expect the
overall compliance rate to be approximately equal to the compliance rate observed in the
treatment group (66.2%).
Adjusted p-values
ITT Estimated Effect Nominal p-value Bonferroni Randomization
Female, Months 1–6 .014 .351 1.000 .895
Female, Months 7–18 .020 .199 1.000 .685
Female, Months 19–30 .033 .014 .085 .077
Male, Months 1–6 -.008 .582 1.000 .991
Male, Months 7–18 .020 .175 1.000 .636
Male, Months 19–30 -.003 .874 1.000 1.000
Adjusted p-values
CACE Estimated Effect Nominal p-value Bonferroni Randomization
Female, Months 1–6 .020 .130 .778 .302
Female, Months 7–18 .034 .009 .055 .026
Female, Months 19–30 .049 .0002 .001 .001
Male, Months 1–6 -.010 .462 1.000 .804
Male, Months 7–18 .028 .028 .169 .076
Male, Months 19–30 -.001 .967 1.000 1.000
Table 3.8: Observed values, nominal p-values, and Bonferroni- and randomization-adjusted
p-values for the six JTPA gender-time groups. Nominal p-values are obtained through ran-
domization tests using 10,000 randomizations.
Using randomization tests and the methods described in Section 3.4, we obtain one set
of nominal ITT p-values and a second set of nominal CACE p-values, listed in the third
column of Table 3.8. Each set contains six p-values, one for each gender-time group. We also
apply Bonferroni and randomization adjustments to both sets of nominal p-values, resulting
in four total sets of adjusted p-values, listed in the rightmost columns of Table 3.8.
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The nominal ITT p-value for the “Female, Months 19–30” group indicates statistical
significance at the α = .05 level. However, after adjusting for multiple comparisons, nei-
ther the Bonferroni- nor randomization-adjusted ITT p-values for this group meets the .05
threshold. Across the six gender-time groups, the randomization-adjusted p-values tend to
be smaller than their Bonferroni-adjusted counterparts; the adjusted p-values are tempered
less when controlling the FWER via the statistics’ joint randomization distribution because
of the correlations among the six nominal p-values.
Overall, the CACE p-values are smaller — more sensitive to complier-only effects —
than the ITT p-values. In particular, the CACE p-values for the “Female, Months 7–18”
and “Female, Months 19–30” groups indicate a much greater level of significance for the esti-
mated effects of JTPA on employment. Applying randomization-based instead of Bonferroni
adjustments to the CACE p-values further increases the indicated significance of these esti-
mated effects. The small randomization-adjusted CACE p-values for these groups suggest
that either an event has occurred that is a priori rare under the sharp null hypothesis of
zero effects, or the sharp null hypothesis is not true — receipt of JTPA services did have an
effect on the employment statuses of females with high school or GED diplomas in their first
and second post-program years. The corresponding ITT p-values, although smallest among
the six groups, are larger and do not have sufficient power to detect an effect on employment
status for any of the gender-time groups.
This increase in power is general. We observe similar p-value trends when comparing
our methods to ITT and Bonferroni analyses on JTPA data without the high school/GED
diploma restriction as well as on other JTPA subgroups analyzed in Bloom et al. (1997).
3.6 Conclusion
We have detailed a randomization-based procedure for analyzing experimental data in the
presence of both non-compliance and multiple testing that is more powerful than traditional
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ITT and Bonferroni analyses. As shown through simulations and analyses of the National
JTPA Study data, a combined randomization-based procedure can be doubly advantageous,
offering gains in power from both perspectives.
A number of other multiple comparisons procedures aim to address the false discovery
rate (FDR) (Benjamini and Hochberg 1995), rather than the FWER. These two error metrics
are conceptually different. We focus on the FWER here; the choice of metric depends on
the particular research setting and goals.
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Appendix A
Marginal Distributions for Chapter 3
Simulations
A.1 Non-compliance
For unit i = 1, . . . , N , the control potential outcomes for compliers and never-takers have
the following marginal distributions:
Yi(0)|Ci = c ∼ Multinomial(.45, .45, .10); (A.1)
Yi(0)|Ci = nt ∼ Multinomial(.02, .02, .96). (A.2)
Under the null hypothesis, Yi(1) has the same marginal distribution as Yi(0) regardless
of compliance status. Under the alternative hypothesis, the complier treatment potential
outcomes follow:
Yi(1)|Ci = c ∼ Multinomial(.80, .10, .10), (A.3)
while the never-taker treatment potential outcomes follow Equation A.2.
A.2 Multiple testing
For unit i = 1, . . . , N and outcome j = 1, 2, 3, the control potential outcomes marginally
follow:
Yij(0) ∼ Multinomial(.45, .45, .10). (A.4)
Under the null hypothesis, Yij(1) has the same marginal distribution as Yij(0). Under the
alternative hypotheses, the treatment potential outcomes have the following marginal distri-
bution:
Yij(1) ∼ Multinomial(.50, .45, .05). (A.5)
A.3 Non-compliance and multiple testing
The potential outcomes follow the marginal distributions described in Appendix A.1.
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Appendix B
Correlation Structure Generation for
Chapter 3 Simulations
To simulate correlation structures among multiple outcomes, we use the following processes
utilizing the marginal distributions described in Appendix A. For units i = 1, . . . , N and
treatment assignment z = 0, 1,
• Zero correlation: all Yij(z) (j = 1, 2, 3) are drawn independently according to their
marginal distributions.
• Partial correlation: Yi1(z) is drawn according to its marginal distribution. With prob-
ability 1/2, Yi2(z) is set equal to the drawn value of Yi1(z); otherwise, Yi2(z) is drawn
independently according to its marginal distribution. Yi3(z) is set equal to Yi1(z) with
probability 1/3, set equal to Yi2(z) with probability 1/3, or drawn independently ac-
cording to its marginal distribution.
• Perfect correlation: Yi1(z) is drawn according to its marginal distribution. Then both
Yi2(z) and Yi3(z) are set equal to the drawn value of Yi1(z).
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